Clarametyx Biosciences Awarded up to $14.2 Million From CARB-X to Accelerate Novel Immune-Enabling Technology to Combat Persistent Bacterial Infections
COLUMBUS, Ohio–(BUSINESS WIRE)–Clarametyx Biosciences Inc. (“Clarametyx”), a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced that CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating antibacterial research and development, has awarded the company up to $14.2 million in funding to advance its novel technology platform through the completion of a Phase 1 clinical study. The award is broken down into a base period totaling $2.4M, with three additional milestone-based options, subject to available funds.
Clarametyx is focused on addressing the challenge of biofilm-associated infections. These infections are often resistant to immune response or standard antibiotic regimens due to an extracellular matrix in the biofilm that protects the bacteria, contributing to persistent, harmful inflammatory responses, as well as extended duration and severity of disease. The Clarametyx platform is designed to precisely remove a universal, pathogen-agnostic target within this matrix, rapidly and effectively collapsing the protective shield and sensitizing bacteria to immune and antibiotic attack.